

Research evaluation

# FINAL RESUME ON THE RESEARCH UNIT:

Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias

# UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:

Université Clermont-Auvergne

## EVALUATION CAMPAIGN 2019-2020 GROUP A

Report published on May, 15 2020



#### In the name of Hcéres<sup>1</sup>:

Nelly Dupin, Acting President

### In the name of the experts committee<sup>2</sup>:

Jose Martinez-Climent, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias, CHELTER, UCA, Mr Marc BERGER



Tables in this document were filled with data submitted by the supervising body on behalf the unit.

## **UNIT PRESENTATION**

Unit name:	Role of intra-clonal heterogeneity and leukemic environment in therapy resistance of chronic leukemias
Unit acronym:	CHELTER
Current label and N°:	EA 7453
ID RNSR:	201722572R
Application type:	Renewal
Head of the unit (2019-2020):	Mr Marc Berger
Project leader (2021-2025):	Mr Marc Berger
Number of teams and/or themes:	1

## **EXPERTS COMMITEE MEMBERS**

Chair:	Mr Jose Martinez-Climent, Universidad de Navarra, Spain
Experts:	Mr François-Xavier Mahon, Université de Bordeaux
	Mr Jean-Max Pasquet, Université de Bordeaux
	Mr Yves Renaudineau, Université de Bretagne Occidentale
	Mr Niclas SETTERBLAD, Sorbonne Paris Cité (supporting personnel)

## **HCÉRES REPRESENTATIVE**

Mr Thierry CAPIOD

## **REPRESENTATIVES OF SUPERVISING BODIES**

Mr Pierre CLAVELOU, Université Clermont Auvergne Mr Vianney DEQUIEDT, Université Clermont Auvergne Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias, CHELTER, UCA, Mr Marc BERGER



## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The EA 7453 CHELTER was created on January 1, 2017, by the former members of the CREaT Hematology Axis and other cellular hematology researchers. The CHELTER unit is located at the Estaing University Hospital Center (CHU), in the Biological Hematology Department (Prof M. Berger) and the Clinical Hematology and Cell Therapy Department (Prof J.O. Bay). A "laboratory" room and two offices at the Medicine and Pharmacy UFR should be assigned to the team in 2020.

#### MANAGEMENT TEAM

Management is provided by head of the unit M. BERGER, Director, and O. TOURNILHAC, Co-Director.

#### HCÉRES NOMENCLATURE

SVE2\_1 Biologie moléculaire et structurale, biochimie

SVE2\_2 Génétique, génomique, bioinformatique, biologie systémique

SVE5 Physiologie, Physiopathologie, Cardiologie, Pharmacologie, Endocrinologie, Cancer, Technologies Médicales

SVE6\_3 Recherche clinique

#### THEMATICS

Role of intra-clonal heterogeneity and leukemic environment in therapy resistance of chronic leukemias.

#### UNIT WORKFORCE

Active staff	Number 06/30/2019	Number 01/01/2021
Full professors and similar positions	4	6
Assistant professors and similar positions	0	2
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions		1
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	0	1
High school teachers	0	
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	4	5
Permanent staff	8	15
Non-permanent professors and associate professors, including emeritus		
Non-permanent full time scientists, including emeritus, post-docs (except PhD students)	1	
PhD Students	1	2
Non-permanent supporting personnel		
Non-permanent staff	2	2
Total	10	17

Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias, CHELTER, UCA, Mr Marc BERGER



## **GLOBAL ASSESSMENT OF THE UNIT**

This team working on two "chronic" and complementary hematological disorders, *i.e.*, Chronic Myeloïd Leukemia (ChML) and Chronic Lymphocytic Leukemia (CLL) has a scientific output of the team that is excellent regarding its capacity to participate in clinical trials, characterize clinical samples, focus the research and develop outstanding national and international partnerships. They propose a clear and realistic scientific program based on current technological development (biology, multi-OMICS and bio-informatic analysis) in parallel with the capacity to obtain competitive and non-competitive funding. The interactions of the CHELTER unit with the non-academic world and the impacts on economy, society, culture or health are limited, and are focused on activities in CML, CLL and Gaucher disease. Unit's life and organization is good and adapted to the size of the team as the team's policy in terms of cohesion and communication goes through a monthly meeting which becomes bi-monthly, the provision of a laboratory notebook and rules for participation in publications and integrity allowing all contributors to be associated. The members of the CHELTER team offer an ambitious and realistic proposal according to the available resources, skills and size of the team.

The evaluation reports of Hceres are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions Evaluation of research Evaluation of doctoral schools Evaluation of programmes International evaluation and accreditation



2 rue Albert Einstein 75013 Paris, France T. 33 (0)1 55 55 60 10

